Till startsida
To content Read more about how we use cookies on gu.se

Contact form


Note! If you want an answer on a question you must specify your email address

Jan Lycke

Professor, adjungerad

Jan Lycke
Professor, adjungerad
+46 31-342 9047

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg

Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Latest publications

Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn et al.
JAMA Neurology, Journal article 2020
Journal article

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova et al.
Scientific reports, Journal article 2019
Journal article

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen et al.
JAMA neurology, Journal article 2019
Journal article

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

Showing 31 - 40 of 73


Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
P. Alping, T. Frisell, Lenka Novakova, P. Islam-Jakobsson, J. Salzer et al.
Annals of Neurology, Journal article 2016
Journal article


Age-dependent effects on the treatment response of natalizumab in MS patients
H. Matell, Jan Lycke, A. Svenningsson, C. Holmen, M. Khademi et al.
Multiple Sclerosis Journal, Journal article 2015
Journal article

Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis
Maria Kneider, Vera Lisovskaja, Jan Lycke, Clas Malmeström, Johannes Jakobsen et al.
Neuroepidemiology, Journal article 2015
Journal article

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study
J. Kuhle, G. Disanto, R. Dobson, R. Adiutori, L. Bianchi et al.
Multiple Sclerosis Journal, Journal article 2015
Journal article


Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: The Swedish experience
Joachim Burman, Ellen Iacobaeus, Anders Svenningsson, Jan Lycke, Martin Gunnarsson et al.
Journal of Neurology, Neurosurgery and Psychiatry, Journal article 2014
Journal article

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Markus Axelsson, Clas Malmeström, Martin Gunnarsson, Henrik Zetterberg, Peter Sundström et al.
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2014
Journal article

Showing 31 - 40 of 73

Page Manager: Katinka Almrén|Last update: 9/1/2015

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2020-04-01